Dashboard Tools Market News Investing Ideas Pricing
Search 100,000+ stocks...
English EN
Deutsch DE Español ES
Sign Up
Log in
Regeneron Pharmaceuticals Inc banner

Regeneron Pharmaceuticals Inc
NASDAQ:REGN

Watchlist Manager
Regeneron Pharmaceuticals Inc Logo
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
Watchlist
Price: 806.42 USD -0.2%
Market Cap: $84.5B
Write Note Create Alert Ask AI

Wall St Price Targets

REGN Price Targets Summary
Regeneron Pharmaceuticals Inc

Wall Street analysts forecast REGN stock price to rise over the next 12 months.

According to Wall Street analysts, the average 1-year price target for REGN is 845.81 USD with a low forecast of 647.41 USD and a high forecast of 1 081.5 USD.

REGN Lowest Forecast
Wall Street Target
$647.41
-20% Downside
REGN Average Forecast
Wall Street Target
$845.81
5% Upside
REGN Highest Forecast
Wall Street Target
$1 081.5
34% Upside
Lowest Forecast
Price Target
647.41 USD
20% Downside
Average Forecast
Price Target
845.81 USD
5% Upside
Highest Forecast
Price Target
1 081.5 USD
34% Upside
Regeneron Pharmaceuticals Inc Competitors:
Price Targets
LAND
Gladstone Land Corp
36% Upside
P
4966
Parade Technologies Ltd
11% Upside
AMP
Amper SA
25% Upside
MRVL
Marvell Technology Group Ltd
22% Upside
LAND
Gladstone Land Corp
36% Upside
P
4966
Parade Technologies Ltd
11% Upside
AMP
Amper SA
25% Upside
MRVL
Marvell Technology Group Ltd
22% Upside

Revenue
Forecast

20% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss
20% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-1%
Average Miss

Over the last 13 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 8 years is 5%.

What are analyst estimates?

Gross Profit
Forecast

19% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss
19% / Year
Past Growth
5% / Year
Estimated Growth
Estimates Accuracy
-5%
Average Miss

Over the last 13 years, the compound annual growth rate for Gross Profit has been 19%. The projected CAGR for the next 8 years is 5%.

What are analyst estimates?

Operating Income
Forecast

18% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
18% / Year
Past Growth
11% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 13 years, the compound annual growth rate for Operating Income has been 18%. The projected CAGR for the next 8 years is 11%.

What are analyst estimates?

Pre-Tax Income
Forecast

22% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss
22% / Year
Past Growth
15% / Year
Estimated Growth
Estimates Accuracy
-16%
Average Miss

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 22%. The projected CAGR for the next 3 years is 15%.

What are analyst estimates?

Net Income
Forecast

15% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss
15% / Year
Past Growth
8% / Year
Estimated Growth
Estimates Accuracy
-15%
Average Miss

Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 8 years is 8%.

What are analyst estimates?

Continue REGN Research

Summary
REGN intrinsic value, competitors valuation, and company profile.
DCF Valuation
REGN stock valuation using Discount Cash Flow valuation method.
Relative Valuation
REGN stock valuation using valuation multiples.
Wall St Estimates
REGN price targets and financial estimates made by Wall Street analysts.
Profitability
Detailed analysis of the company's profitability.
Solvency
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
REGN stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall St Estimates
Profitability
Solvency
Financials
Discount Rate
Other Regeneron Pharmaceuticals Inc listings:
F • EUR
RGO
 XBER • EUR
RGO
 LSE • USD
0R2M
Discover More
Why do you have more estimates than other sites?

Our estimates are sourced from the pool of sell-side and buy-side analysts that we have access to. What you see on other sites is mostly sourced from sell-side analysts.

What is REGN's stock price target?
Price Target
845.81 USD

According to Wall Street analysts, the average 1-year price target for REGN is 845.81 USD with a low forecast of 647.41 USD and a high forecast of 1 081.5 USD.

What is the Revenue forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Revenue has been 20%. The projected CAGR for the next 8 years is 5%.

What is the Gross Profit forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
5%

Over the last 13 years, the compound annual growth rate for Gross Profit has been 19%. The projected CAGR for the next 8 years is 5%.

What is the Operating Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
11%

Over the last 13 years, the compound annual growth rate for Operating Income has been 18%. The projected CAGR for the next 8 years is 11%.

What is the Pre-Tax Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
15%

Over the last 13 years, the compound annual growth rate for Pre-Tax Income has been 22%. The projected CAGR for the next 3 years is 15%.

What is the Net Income forecast for Regeneron Pharmaceuticals Inc?
Projected CAGR
8%

Over the last 13 years, the compound annual growth rate for Net Income has been 15%. The projected CAGR for the next 8 years is 8%.

Back to Top
ALPHA SPREAD
Follow us
Join 352,400+ value investors using Alpha Spread
Create Free Account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Valuation Backtest Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks Wide Economic Moat Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2026 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

AI Assistant
Get AI-powered insights for any company or topic.
Open AI Assistant
Other Tools
Stock Screener
Discover stocks
Stock Comparison
Smarter decisions through side-by-side analysis
Intrinsic Value Calculator
Discover the true worth of your stocks
DCF Value Calculator
Harness the power of DCF

Intrinsic Value is all-important and is the only logical way to evaluate the relative attractiveness of investments and businesses.

Warren Buffett